International diffusion of new health technologies: A ten-country analysis of six health technologies

International Journal of Technology Assessment in Health Care

Volumn 22, Issue 4, 2006, Pages 419-428

  Packer, Claire ^a   Simpson, Sue ^a   Stevens, Andrew ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Diffusion of innovation; Forecasting; Health technology; International; Technology assessment

Indexed keywords

DECISION MAKING; DIFFUSION; DRUG PRODUCTS; ENZYME INHIBITION; HEALTH CARE; NEUROLOGY; PUBLIC POLICY;

BRAIN STIMULATORS; HEALTH TECHNOLOGY; INNOVATION DIFFUSION; TECHNOLOGY ASSESSMENT;

BIOMEDICAL ENGINEERING;

BENZOPORPHYRIN DERIVATIVE; BETA INTERFERON; CYCLOOXYGENASE 2 INHIBITOR; SILDENAFIL;

ALARM MONITORING; ARTICLE; AUSTRALIA; BIOMEDICAL TECHNOLOGY ASSESSMENT; BRAIN DEPTH STIMULATION; CANADA; CORONARY STENT; DECISION MAKING; DENMARK; DRUG ELUTING STENT; EVIDENCE BASED MEDICINE; FORECASTING; FRANCE; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; NETHERLANDS; NORWAY; SPAIN; SWEDEN; SWITZERLAND; UNITED KINGDOM;

AUSTRALIA; BIOMEDICAL TECHNOLOGY; CANADA; DEEP BRAIN STIMULATION; DIFFUSION OF INNOVATION; DRUG DELIVERY SYSTEMS; DRUG THERAPY; EUROPE; HEALTH EXPENDITURES; HUMANS; POLICY MAKING; RETROSPECTIVE STUDIES; STENTS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 33750373148     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462306051336     Document Type: Article

References (28)

1. Baker LC, Wheeler SK. Managed care and technology diffusion: The case of MRI. Health Aff (Millwood). 1998;17:195-207.
2. Banta HD, Vondeling H. Diffusion of minimally invasive therapy in Europe. Health Policy. 1993;23:125-133.
3. Blume S. Early warning in the light of theories of technological change. Int J Technol Assess Health Care. 1998;14:613-623.
4. Bryce C, Cline K. The supply and use of selected medical technologies. Health Aff (Millwood). 1998;17:213-224.
5. Dent THS, Sadler M. From guidance to practice: Why NICE is not enough. BMJ. 2002;324:842-845.
6. Greenhalgh T, Robert G, MacFarlane F et al., Diffusion of innovations in service organizations: Systematic review and recommendations. Milbank Q. 2004;82:581-629.
7. Harrison A, Dixon J, New B, et al. Funding the NHS. Can the NHS cope in future? BMJ. 1997;314:139-142.
8. HM Treasury. Securing our future health: Taking a long-term view. Interim report. London: HM Treasury; 2001.
9. Konig HH. Diffusion of high-cost medical devices: Regulations in four European Union members states. In: Leidl R, ed. Health care and its financing in the single European market. Amsterdam: IOS Press; 1998:150-166.
10. Lázaro P, Fitch K. The distribution of 'big ticket' medical technologies in OECD countries. Int J Technol Assess Health Care. 1995;11:552-570.
11. Marshall D, Hailey D, Jonsson E. Health policy on bone density measurement technology in Sweden and Australia. Health Policy. 1996;35:217-228.
12. McClellan M, Kessler D, for the TECH investigators. A global analysis of technological change in health care: The case of heart attacks. Health Aff (Millwood). 1999;18:250-255.
13. McClellan M, Kessler D. Technological change in health care. A global analysis of health attack. Michigan: University of Michigan Press; 2002.
14. Mohr PE, Mueller C, Neuman P, et al. The impact of medical technology on future health care costs. Bethesda, MD: Project HOPE; 2001.
15. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. London: National Institute for Clinical Excellence; 2002.
16. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: National Institute for Clinical Excellence; 2001.
17. National Institute for Clinical Excellence. Guidance on the use of photodynamic therapy for age-related macular degeneration. London: National Institute for Clinical Excellence; 2003.
18. Notzon F, Placek P, Taffel S. Comparisons of national cesarean-section rates. N Engl J Med. 1987;316:386-389.
19. Organisation for Economic Co-operation and Development. Health data 2003. Paris: OECD Publishing; 2003.
20. Organisation for Economic Co-operation and Development. OECD Health Project: Health technologies and decision making. Paris: OECD Publishing; 2005.
21. Organisation for Economic Co-operation and Development. OECD population data. Available at: http://www.oecd.org/dataoecd/12/46/31963800.xls. Accessed May 2005.
22. Rogers E. Diffusion of innovations. New York: The Free Press; 1995.
23. Rosenau P. Managing medical technology: Lessons for the United States from Quebec and France. Int J Health Serv. 2000;30:617-639.
24. Ryan J, Piercy J, James P. Assessment of NICE guidance on two surgical procedures. Lancet. 2004;363:1525-1526.
25. Sheldon TA, Cullum N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes, and interviews. BMJ. 2004;329:999-1004.
26. Slade EP, Anderson GF. The relationship between per capita income and diffusion of medical technologies. Health Policy. 2001;58:1-14.
27. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: World Health Organization; 2001.
28. Wilking N, Jönsson B. A pan-European comparison regarding patient access to cancer drugs. Sweden: Karolinska Institutet; 2005.